Workplace
COVID-19 Testing
Bring the lab to your lobby
Employers are under more pressure than ever to protect the health and safety of their employees.
64% Employees would like their employers to offer testing services, even after vaccination. Yet more than 30% employers are not conducting testing citing concerns about cost, complexity and accuracy1,2.
Why do companies choose not to test?
30%
Think it’s
too costly
29%
Too complicated
to implement
19%
Concerned about
test accuracy
11%
Lack of knowledge
or information
13%
Time to
obtain results
Testing Strategies for COVID-19
There are a range of testing strategies for COVID-19: Diagnostic, Screening and Surveillance. Further information on each type of strategy including their intended use and applications, regulatory requirements, and reporting requirements can be found here
COVID-19 Tests available from LumiraDx
Surveillance:
LumiraDx SARS-CoV-2 Ag Surveillance Test
Up to five swabs in one test.
Monitor prevalence of the virus in your population.
For surveillance testing only, not for diagnostic use
The LumiraDx SARS-CoV-2 Ag Surveillance Test has not been cleared, approved, or authorized by FDA. This test should be used for surveillance purposes (i.e., to inform population or community-level decision-making on de-identified specimens) only. FDA does not regulate surveillance tests.
FIND OUT MORE
Diagnostic:
LumiraDx SARS-CoV-2 Ag Test
- Authorized for individuals suspected of COVID-19 within 12 days of symptom onset
- 97.6% positive agreement and 96.6% negative agreement with RT-PCR
- Authorized for screening asymptomatic individuals when tested twice over three days with at least 24 hours (and no more than 48 hours) between tests
- Results in 12 minutes
Sources
1. Jezior, Melissa. “Employees Share Views on Covid-19 Vaccines and the Return to Work.” 2021 Eagle Hill Consulting COVID-19 Vaccines and the Workplace Survey, Eagle Hill Consulting, 3 June 2021, www.eaglehillconsulting.com/insights/employee-views-vaccines-workplace/
2. Wade, Nathaniel L, and Mara G Aspenall. “Back to the Workplace: Are We There Yet? Key Insights from Employers One Year into the Pandemic.” COVID-19 Diagnostics Commons, Arizona State University, Apr. 2021, https://issuu.com/asuhealthsolutions/docs/asu_workplace_commons_phase_2_report?fr=sZGIwZjE5NTg1NjM
LumiraDx SARS-CoV-2 Ag Test has not been cleared or approved by FDA. The LumiraDx SARS-CoV-2 Ag test has been authorized by FDA under an EUA only for the detection of SARS-CoV-2 nucleocapsid protein. The test has not been authorized for use to detect any other viruses or pathogens. The test is authorized in the United States for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
The LumiraDx SARS-CoV-2 Ag Surveillance Test has not been cleared, approved, or authorized by FDA. This test should be used for surveillance purposes (i.e., to inform population or community-level decision-making on de-identified specimens) only. FDA does not regulate surveillance tests.
BetterHealthExperiencesOutcomes
Supporting healthier lives, for individuals, communities and wider society
Enabling responsive, personal relationships between patients and care teams.
Controlling and reducing costs to help ease pressure on healthcare budgets.